Pharmacotherapy for Type 2 Diabetes Mellitus: What’s Up and Coming in the Glucagon-Like Peptide-1 (GLP-1) Pipeline?

Glycemic Control ◽

Glucagon Secretion ◽

New Drugs ◽

Beneficial Effects ◽

Glucagon Like Peptide ◽

Glucagon-like peptide-1 (GLP-1), an incretin hormone, is known to lower glucose levels, suppress glucagon secretion, and slow gastric emptying. These properties make GLP-1 an ideal target in treating type 2 diabetes mellitus (T2DM). There are many FDA-approved GLP-1 agonists on the market today, several of which have demonstrated benefit beyond improving glycemic control. Given the beneficial effects of GLP-1 agonists in patients with T2DM, new drugs are in development that combine the mechanism of action of GLP-1 receptor agonism with novel mechanisms and with drugs that promote GLP-1 secretion. These agents are designed to improve glycemic control and target greater body weight reduction. This article discusses new GLP-1 drugs in the pipeline for the treatment of T2DM.

Cardiovascular safety and glycemic control of glucagon-like peptide-1 receptor agonists for type 2 diabetes mellitus: A pairwise and network meta-analysis

Diabetes Research and Clinical Practice ◽

10.1016/j.diabres.2012.09.004 ◽

2012 ◽

Vol 98 (3) ◽

pp. 386-395 ◽

Cited By ~ 22

Author(s):

Feng Sun ◽

Kai Yu ◽

Shanshan Wu ◽

Yuan Zhang ◽

Zhirong Yang ◽

...

Keyword(s):

Diabetes Mellitus ◽

Type 2 Diabetes ◽

Glycemic Control ◽

Meta Analysis ◽

Cardiovascular Safety ◽

Receptor Agonists ◽

Glucagon Like Peptide ◽

Low dose Glucagon Like Peptide-1 analogue (GLP-1) improves glycemic control, medical adherence and DTSQ in patients with type 2 diabetes mellitus on peritoneal dialysis

10.26226/morressier.59a56f96d462b8028d895c0f ◽

2017 ◽

Author(s):

Takeyuki Hiramatsu

Keyword(s):

Diabetes Mellitus ◽

Type 2 Diabetes ◽

Peritoneal Dialysis ◽

Glycemic Control ◽

Low Dose ◽

Medical Adherence ◽

Glucagon Like Peptide ◽

Glucagon-like peptide-1 receptor agonists as insulin add-on therapy in patients with inadequate glycemic control in type 2 diabetes mellitus: lixisenatide as a new therapeutic option

International Journal of Clinical Pharmacology and Therapeutics ◽

10.5414/cp202052 ◽

2015 ◽

Vol 53 (03) ◽

pp. 230-240 ◽

Cited By ~ 2

Author(s):

Ricardo Gómez-Huelgas ◽

Sharona Azriel ◽

Manel Puig-Domingo ◽

Josep Vidal ◽

Pedro de Pablos-Velasco

Keyword(s):

Diabetes Mellitus ◽

Type 2 Diabetes ◽

Glycemic Control ◽

Therapeutic Option ◽

Receptor Agonists ◽

Glucagon Like Peptide ◽

Glucagon Like Peptide 1 ◽

Inadequate Glycemic Control

Combination of Premixed Insulin with Glucagon-Like Peptide-1 Receptor Agonist (GLP-1) for Uncontrolled Type 2 Diabetes Mellitus (T2DM) Patients

Diabetes ◽

10.2337/db18-2231-pub ◽

2018 ◽

Vol 67 (Supplement 1) ◽

pp. 2231-PUB

Author(s):

SASAN FAZELI ◽

NICOLE EHRHARDT

Keyword(s):

Diabetes Mellitus ◽

Type 2 Diabetes ◽

Receptor Agonist ◽

Premixed Insulin ◽

Glucagon Like Peptide ◽

Pharmacogenetics of Glucagon-like Peptide-1 Agonists for the Treatment of Type 2 Diabetes Mellitus

Current Clinical Pharmacology ◽

10.2174/1574884713666180221121512 ◽

2018 ◽

Vol 12 (4) ◽

pp. 202-209 ◽

Cited By ~ 3

Author(s):

Spyridon N. Karras ◽

Eleni Rapti ◽

Theocharis Koufakis ◽

Angeliki Kyriazou ◽

Dimitrios G. Goulis ◽

...

Keyword(s):

Diabetes Mellitus ◽

Type 2 Diabetes ◽

Glucagon Like Peptide ◽

Effect of glucagon‐like peptide‐1 receptor agonists in subjects with type 2 diabetes mellitus: a meta‐Analysis

International Journal of Clinical Practice ◽

10.1111/ijcp.14400 ◽

2021 ◽

Author(s):

Weiyun Qian ◽

Fei Liu ◽

Qichao Yang

Keyword(s):

Diabetes Mellitus ◽

Type 2 Diabetes ◽

Meta Analysis ◽

Receptor Agonists ◽

Glucagon Like Peptide ◽

Cigarette smoking, type 2 diabetes mellitus, and glucagon-like peptide-1 receptor agonists as a potential treatment for smokers with diabetes: An integrative review

Diabetes Research and Clinical Practice ◽

10.1016/j.diabres.2019.01.033 ◽

2019 ◽

Vol 149 ◽

pp. 78-88 ◽

Cited By ~ 2

Author(s):

Luba Yammine ◽

Thomas R. Kosten ◽

Maria Pimenova ◽

Joy M. Schmitz

Keyword(s):

Diabetes Mellitus ◽

Type 2 Diabetes ◽

Cigarette Smoking ◽

Integrative Review ◽

Potential Treatment ◽

Receptor Agonists ◽

Glucagon Like Peptide ◽

Co-Purification of Recombinant Modified Glucagon-Like and Glucose-Dependent Insulinotropic Peptide to Create a Two-Component Drug for the Treatment of Type 2 Diabetes Mellitus and Obesity

Biotekhnologiya ◽

10.21519/0234-2758-2021-37-6-74-83 ◽

2021 ◽

Vol 37 (6) ◽

pp. 74-83

Author(s):

A.Yu. Gorbunova ◽

E.P. Sannikova ◽

I.I. Gubaidullin ◽

O.M. Ignatova ◽

M.Yu. Kopaeva ◽

...

Keyword(s):

Diabetes Mellitus ◽

Type 2 Diabetes ◽

Mouse Model ◽

Specific Activity ◽

Two Component ◽

Glucagon Like Peptide ◽

Glucagon Like Peptide 1 ◽

Insulinotropic Peptide

In addition to the previously developed recombinant modified human glucagon-like peptide 1 (rmglp1, Glypin), a recombinant modified human glucose-dependent insulinotropic peptide (RMGIP) has been obtained. A new universal reverse-phase HPLC technique has been proposed allowing quantitative analysis of rmGlp1 and rmGip separately and as part of a two-component preparation. The data show that the design of recombinant human rmGip according to the Glypine formula makes it possible to produce one-component and two-component preparations containing various rmGip and rmGlp1 protein ratios ranging from 1:0 to 20:1, using cell biomass samples mixed in predetermined proportions. Studies of human rmGip activity in a mouse model revealed reduced specific activity and signs of weak antagonistic effects. In this regard, there is a need for further study of human rmGip activity in a mouse model, including the use of alternative mouse or rat rmGip. type 2 diabetes mellitus; two-component drug, glucose-dependent insulinotropic peptide, glucagon-like peptide-1 The work was supported by the Internal Grant from National Research Center Kurchatov Institute.